Welcome to our dedicated page for QT Imaging Holdings SEC filings (Ticker: qti), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QT Imaging Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QT Imaging Holdings's regulatory disclosures and financial reporting.
Taylor Ross reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings director Taylor Ross received an equity grant of 3,500 shares of Common Stock on March 20, 2026, at no cash cost. Following this award, Ross directly holds 60,578 shares. The grant is in the form of Restricted Stock Units that vest in four equal installments on May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027, subject to continued service. All units vest immediately if there is a Change of Control under the company’s 2024 Equity Incentive Plan.
QT Imaging Holdings director Zeev Weiner increased his stake through equity compensation transactions. On March 17, 2026 he exercised stock options covering 23,054 shares of Common Stock at exercise prices of $2.2452 and $1.9950 per share, retaining the acquired shares. On March 20, 2026 he received a grant of 3,500 shares of Common Stock at no cost, reflecting a restricted stock unit award that vests in four equal installments between May 15, 2026 and February 15, 2027, with full vesting upon a Change of Control. Following these transactions, he directly holds 55,093 shares of Common Stock, and the filing indicates all reported derivative option positions tied to these exercises have been fully exercised.
GREENE JAMES S reported acquisition or exercise transactions in this Form 4 filing.
QT IMAGING HOLDINGS, INC. director James S. Greene reported an equity award of 3,500 shares of Common Stock, bringing his direct holdings to 3,500 shares. The award is structured as Restricted Stock Units that vest 25% on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027, subject to his continued service. All RSUs will fully vest immediately if there is a Change of Control as defined in the company’s 2024 Equity Incentive Plan.
Jennings Jay Walter reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that Chief Financial Officer Jay Walter Jennings received a grant of 2,800 shares of common stock on March 20, 2026 as a stock award. The grant price per share was $0.00, and his direct holdings after the award total 2,800 shares.
According to the vesting schedule, one-third of the related restricted stock units vest on May 15, 2027, with the remaining two-thirds vesting in eight equal quarterly installments on each subsequent August 15, November 15, February 15, and May 15, so that the grant is fully vested on May 15, 2029. All such units will immediately vest if there is a Change of Control as defined in the company’s 2024 Equity Incentive Plan.
Dinu Raluca reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that Chief Executive Officer Raluca Dinu received equity awards of common stock as compensation. On March 20, 2026, she was granted 3,500, 500,000, and 16,000 shares of common stock at a price of $0.00 per share under the company’s equity plan.
After these awards, the filing shows she directly owns 908,845 common shares. Footnotes explain these are restricted stock units with vesting schedules running from May 15, 2026 through dates as late as February 15, 2030 or May 15, 2029, with full acceleration upon a qualifying Change of Control.
Katz Avi S reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. chairman Avi S. Katz received a grant of 3,500 shares of common stock on March 20, 2026 as a stock award, at a stated price of $0.00 per share. Following this grant, he directly holds 416,952 common shares.
The award is structured as restricted stock units. Subject to his continued service, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027. All RSUs will vest immediately if the company undergoes a Change of Control under its 2024 Equity Incentive Plan.
DICKSON DANIEL H reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. director Daniel H. Dickson reported receiving a grant of 3,500 shares of Common Stock, awarded as restricted stock units at a stated price of $0.0000 per share. Following the award, he directly holds 32,039 Common shares.
According to the vesting terms, subject to his continued service to the company, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027. All RSUs will vest immediately upon a qualifying Change of Control under the company’s 2024 Equity Incentive Plan. The filing also notes that the reported beneficial ownership reflects a 3-for-1 reverse stock split effective October 23, 2025.
QT Imaging Holdings, Inc. released an investor presentation highlighting rapid commercial growth for its breast imaging platform and updated financials. Revenue reached $18.9 million in 2025, up from $4.9 million in 2024, driven by shipment of 40 QT Breast Acoustic CT scanners under distribution agreements.
Q4 2025 revenue was $8.3 million, an 877% year-over-year increase, with 38% gross margin and a net loss of $1.4 million. Adjusted EBITDA improved to $(0.4) million from $(1.9) million a year earlier. The company ended 2025 with $10.5 million in cash after an oversubscribed $18.2 million private placement and new debt financing, and it expects approximately $39 million of revenue in 2026, including initial SaaS cloud platform contributions.
QT Imaging Holdings, Inc. reported preliminary unaudited results showing record revenue of $8.3 million in Q4 2025 and $18.9 million for full-year 2025, exceeding its $18 million outlook. Q4 revenue rose 877% year over year and 97% sequentially, driven by shipment of 17 Breast Acoustic CT™ scanners.
For 2025, revenue grew 288% versus 2024, with 40 scanners shipped. Gross margin was 45% for the year and 38% in Q4. Despite this growth, the company recorded a 2025 net loss of $21.1 million, influenced by $8.8 million of other expense tied to term loan issuance, note extinguishments and fair value changes.
Non-GAAP Adjusted EBITDA improved to $(3.5) million from $(7.4) million in 2024, while net cash used in operating activities narrowed to $9.0 million. Cash, restricted cash and equivalents reached $10.5 million at year-end 2025 after an $18.2 million private placement and new debt financings. The company relisted on Nasdaq and is pivoting from pure hardware to a SaaS and biomarker-driven imaging platform, and it projects 2026 revenue of about $39 million, including initial SaaS Cloud Platform contributions.
Alyeska Investment Group and related parties reported a sizable position in QT Imaging Holdings, Inc. common stock. As of December 31, 2025, they beneficially owned 1,178,317 shares, representing 9.99% of the company’s common stock.
The position is held through 670,683 common PIPE shares, pre-funded warrants for 440,427 shares, and warrants for 1,111,111 shares. These warrants are subject to a 9.9% beneficial ownership limitation, meaning they can only be exercised to a level where Alyeska would hold up to 9.9% of QT Imaging’s outstanding common stock after exercise.
The ownership figures are based on 11,902,198 shares outstanding, as disclosed in QT Imaging’s prospectus dated December 31, 2025. Alyeska certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.